Additionally, meta-analyses of randomised trials with a duration of over 12 months have indicated that most glucose-lowering therapies have no significant impact on stroke risk, except for thiazolidinediones and GLP-1 RAs [79]. The gene discussed is GLP1R; the disease is stroke disorder.